CardiacSense
Medical Watch for Detecting and Monitoring Heart Arrhythmias
Company Overview
Snapshot
Founded in December 2009 by Eldad Shemesh, CardiacSense operates with 11–50 employees. The company has raised $24.43 million across 9 funding rounds from 7 investors. In January 2023, CardiacSense secured FDA clearance for its medical-grade watch.
Business overview
CardiacSense develops and markets a medical wearable watch designed for long-term, continuous monitoring of heart arrhythmias, such as atrial fibrillation or cardiac arrest, and blood pressure. The company's technology leverages optics, mechanics, and signal processing, backed by a strong IP portfolio, to provide highly accurate vital sign monitoring. Serving the health tech and life sciences sector, CardiacSense enables big data analysis and AI-backed healthcare solutions for patients, providers, and insurance companies.
Strategic signal
In January 2023, CardiacSense received FDA clearance for its medical-grade watch. This regulatory approval is a significant validation of the device's accuracy and safety, positioning CardiacSense to expand its market presence in the United States and reinforcing investor confidence in its medical wearable technology.
Log in to access full profile ›Company Intelligence Q&A
- What is CardiacSense's core product?
- CardiacSense's core product is a medical wearable watch designed for continuous, long-term monitoring of heart arrhythmias and blood pressure.
- When did CardiacSense receive FDA clearance for its medical watch?
- CardiacSense received FDA clearance for its medical-grade watch in January 2023.
- What was a key strategic partnership for CardiacSense in April 2020?
- In April 2020, CardiacSense partnered with Homestay Care (ASX:HSC) for cardiac wearables, expanding its distribution and reach.